Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | CASP6 | P55212 | 1/20 | 0.33 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25221783 | 1.00 | P2RX7 (0.38) | P2RX7MAPK1POLBCASP6CTDSP1 | |
| SCHEMBL16336454 | 1.00 | P2RX7 (0.38) | P2RX7MAPK1POLBCASP6CTDSP1 | |
| SCHEMBL18059655 | 0.86 | P2RX7 (0.43) | P2RX7MAPK1USP30 | |
| SCHEMBL14247785 | 0.86 | P2RX7 (0.43) | P2RX7MAPK1POLBCASP6CTDSP1 | |
| SCHEMBL20396266 | 0.83 | P2RX7 (0.48) | P2RX7MAPK1POLBCASP6CTDSP1 | |
| SCHEMBL16386070 | 0.82 | GAA (0.39) | USP30 | |
| SCHEMBL19338242 | 0.77 | P2RX7 (0.38) | P2RX7MAPK1 | |
| SCHEMBL18797246 | 0.75 | P2RX7 (0.39) | P2RX7MAPK1POLBCASP6CTDSP1 | |
| SCHEMBL18797248 | 0.75 | P2RX7 (0.39) | P2RX7MAPK1POLBCASP6CTDSP1 | |
| SCHEMBL18797247 | 0.75 | P2RX7 (0.39) | P2RX7MAPK1POLBCASP6CTDSP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230174481-A1 | KINASE INHIBITORS | VIDYA THERAPEUTICS, INC. | 2023-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230174481-A1 | KINASE INHIBITORS | BTK, LYN, LCK | P2RX7 2034/4885MAPK1 239/4885POLB 2274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.